Antibody-drug conjugates or ADCs are a new class of highly potent biopharmaceutical drugs designed as a targeted therapy for the treatment of people with cancer. ADCs are complex molecules composed of an antibody linked - via a stable, chemical linker with labile bonds - to a biological active cytotoxic (anticancer) payload or drug.


By combining the unique targeting capabilities of monoclonal antibodies with the cancer-killing ability of cytotoxic drugs, antibody-drug conjugates allow sensitive discrimination between healthy and diseased tissue. This means that, in contrast to traditional chemotherapeutic agents, antibody-drug conjugates target and attack the cancer cell so that healthy cells are less severely affected.


MedKoo provides a wide range of services to support the characterization of various forms of antibodies that can be applied to antibody drug conjugates, which includes almost all the monoclonal and engineered antibodies on our website. Our scientists are pleased to offer site-specific antibody-drug conjugation services based on traditional strategy as well as unique conjugation strategy developed at Medkoo. Small drugs or toxins can be conjugated to an antibody at a specific site away from the antigen binding site.


We offer a series of Antibody-Drug Conjugation Services